top of page

China Diabetes Cure Cost (2026): Stem Cell Treatment Prices and What International Patients Should Know

By

ChinaCureLink

Mon May 18 2026

8 min read

May 18
8 min read

Updated: Oct 23

Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink


Key Takeaways

  1. Official price: The China diabetes cure cost now has an official benchmark. Stem cell therapy for type 2 diabetes in Boao Lecheng costs 58,000 yuan (about US$8,600) per infusion, or 174,000 yuan (about US$25,800) for a full three-infusion course.

  2. Regulated program: Boao Lecheng approved this treatment in January 2026, which is why it has a published price.

  3. Type 1 has no commercial price yet: Stem cell islet therapy for type 1 diabetes is still limited to research studies in China.

  4. Budget beyond treatment: Flights, about three weeks of accommodation and a companion's costs are extra.

Introduction


The cost of a China diabetes cure is one of the first questions international families ask, and in 2026 it finally has an official answer for type 2 diabetes. For many patients living with Type 1 or Type 2 diabetes, the daily reality of insulin injections, glucose monitoring, medication adjustments, and long-term complication risks can become emotionally and physically exhausting. This has led growing numbers of international families to explore emerging regenerative medicine approaches — including diabetes stem cell treatment in China.


China has emerged as one of the most active research centers globally for stem cell and cell-based diabetes therapies, particularly in pancreatic islet regeneration and insulin-producing beta cell transplantation. While these treatments remain experimental or selectively regulated in many countries, some Chinese hospitals and pilot medical zones now offer access through clinical programs and regulated medical technology pathways.


Table of Content


Average Cost of Diabetes Stem Cell therapy Treatment in China


Current pricing for diabetes stem cell therapy in China, based on officially published figures:

Treatment

Price per infusion

Full course (3 infusions)

UC-MSC stem cell therapy for type 2 diabetes, Boao Lecheng

About US$8,600 (58,000 yuan), 50 million cells

About US$25,800 (174,000 yuan)

Stem cell islet therapy for type 1 diabetes

No commercial price (research studies only)

—


What the Price Includes

  • Preparation of the stem cells

  • The infusions

  • Medical monitoring during treatment, including continuous glucose monitoring


What to Budget for Separately

  • Flights to Hainan for the patient and a companion

  • Accommodation for around three weeks

  • A companion's meals and local transport

  • Any pre-treatment tests the hospital requests

  • Interpreter and on-site support, if not arranged through a facilitator


The treatment is self-paid. Patients should request a written, itemized quote from the hospital before travelling.


Want to know the full cost for a specific case?




Why Is Stem Cell Therapy Cheaper in China?


Compared with the United States or parts of Europe, treatment costs in China are often significantly lower due to:


  • Lower hospital operational costs

  • Large-scale cell manufacturing infrastructure

  • Government-supported biotechnology investment

  • Higher patient treatment volumes

  • Faster clinical translation environments


In the United States, no stem cell therapy for type 2 diabetes has been approved for routine use, so patients there cannot buy an equivalent regulated treatment at any price. In China, the Boao Lecheng program offers a regulated option with a published price per infusion.


What Types of Diabetes Are Being Treated?


Type 1 Diabetes


Most advanced stem cell diabetes research focuses on Type 1 diabetes, where autoimmune destruction damages insulin-producing pancreatic beta cells. For type 1 specifically, see type 1 diabetes breakthroughs in China.


Chinese research groups have explored:


  • Stem cell-derived islet transplantation

  • Autologous stem cell approaches

  • Beta-cell regeneration

  • Immune-modulating regenerative therapy


Chinese research teams have restored natural insulin production in type 1 patients, with results from the Peking University programme now lasting nearly three years. These islet treatments are still available only within clinical research studies, so there is currently no commercial China type 1 diabetes cure cost to quote. Other type 1 options in China are priced after a specialist assessment. They are covered in Did China Cure Diabetes? 2026 Treatments & Access.



Learn about the groundbreaking research, treatment approach, and what it could mean for people with Type 1 diabetes.


Type 2 Diabetes


Stem cell approaches for Type 2 diabetes generally focus on:


  • Improving insulin sensitivity

  • Reducing systemic inflammation

  • Supporting pancreatic function

  • Delaying progression


A widely discussed 2024 Chinese case report described a patient becoming insulin-free following stem cell-derived pancreatic cell transplantation, though experts caution that broader evidence is still needed before conclusions can be generalized. Type 2 diabetes is currently the only form with an approved, priced stem cell treatment in China (see the price table above).



Learn the step-by-step treatment process, eligibility, and how international patients can access stem cell therapy in China.

What Affects the Cost?


Several factors influence pricing:


1. Type of Stem Cells Used


Costs vary depending on whether therapy uses:


  • Autologous stem cells (patient-derived)

  • Donor-derived mesenchymal stem cells

  • Induced pluripotent stem cells (iPSC)

  • Stem cell-derived pancreatic islet cells


More sophisticated cellular engineering significantly increases cost.


2. Number of Treatment Cycles


Some patients undergo:

  • Single infusion protocols

  • Multiple infusion cycles

  • Long-term regenerative programs


Additional cycles increase total expenses. The Boao program is priced per infusion, and a standard course is three infusions given one week apart.


3. Hospital Tier and Location


Top Class 3A hospitals and internationally oriented medical centers generally charge more due to:


  • Advanced laboratory facilities

  • International patient departments

  • Specialized endocrinology teams

  • Higher safety oversight


4. Length of Stay


Programs can range from:


  • 7-day protocols

  • 2–3 week inpatient monitoring

  • Extended rehabilitation or follow-up periods


Accommodation and interpreter support also affect final costs. The Boao program typically requires around three weeks in Hainan, covering evaluation and three weekly infusions.


Is Diabetes Stem Cell Therapy Approved in China?


This is an important question. Stem cell therapy in China exists within a regulated but evolving framework. Not all therapies are fully approved commercial treatments.


Currently, access may occur through:


  • Hospital-based clinical research programs

  • Medical technology pilot zones

  • Regulated investigational pathways

  • Government-approved stem cell clinical studies


China’s Hainan Boao Lecheng Pilot Zone has become particularly known for allowing selected advanced medical technologies under regulatory supervision.


In January 2026, Boao Lecheng approved umbilical cord mesenchymal stem cell (UC-MSC) therapy for type 2 diabetes as a clinical treatment at Ciming Boao International Hospital. The approval is what allows the program to publish an official price. The full treatment protocol is explained in the type 2 diabetes stem cell therapy guide.


At the same time, international patients should understand:


  • Not all clinics are legitimate

  • Outcomes vary substantially

  • Some therapies remain experimental

  • Long-term durability data is still limited

  • Immune rejection and procedural risks may exist


Learn about stem cell therapy types, eligibility, and the complete treatment process for diabetes in China.


Clinical Results: What Does Current Research Show?


Several Chinese and international research groups have reported encouraging findings in early-stage studies.

Reported outcomes include:


  • Reduced insulin dependence

  • Improved HbA1c levels

  • Better glucose stability

  • Improved C-peptide production

  • Functional remission in selected patients


In 2026, a hospital team in Shenzhen reported that 30 type 1 diabetes patients had stopped insulin using an integrative medicine approach, though these results have not yet been peer-reviewed.


Meanwhile, a Chinese patient treated with stem cell-derived islets has stayed off insulin since 2023, and a Chinese Academy of Sciences update in 2026 reported the programme's results lasting nearly three years.


Still, experts emphasize that:


  • Larger randomized trials are needed

  • Long-term efficacy remains uncertain

  • Patient selection is critical

  • Some patients may not respond


How International Patients Typically Access Treatment


Medical Record Review

The process starts with recent records: HbA1c, C-peptide, kidney function, current medicines and insulin doses, and continuous glucose data if available. A records review is free and helps avoid travel costs for patients who would not qualify.


Eligibility Assessment

Specialists confirm the diabetes type and stage. Boao's stem cell therapy is best suited to type 2 patients whose blood sugar stays poorly controlled despite several medicines or insulin, especially those with some remaining islet function.


Treatment Planning

The hospital confirms the number of infusions and issues a written, itemized quote, so patients know the total treatment cost before booking travel.


Travel and Coordination

Patients plan around three weeks in Hainan. Visa and travel details are covered in the China Medical Visa Guide.


Have recent test results? → Request a Preliminary Case Review



China vs U.S. Stem Cell Diabetes Treatment


China has become one of the most active environments globally for regenerative diabetes research due to substantial investment in biotechnology and translational medicine infrastructure.


China

United States

Type 2 diabetes stem cell therapy

Approved in Boao Lecheng (2026), published price

No approved stem cell therapy

Type 1 diabetes cell therapy

Stem cell islets in research studies

Donor islet therapy (Lantidra) FDA-approved in 2023; stem cell islets in trials

Price transparency

Official price per infusion

Not applicable for type 2

FAQ: Frequently Asked Questions


How much does a diabetes cure cost in China?

In Boao Lecheng, stem cell therapy for type 2 diabetes costs 58,000 yuan (about US$8,600) per infusion, or 174,000 yuan (about US$25,800) for a full three-infusion course. Travel and accommodation are extra.


How much does a type 1 diabetes cure cost in China?

There is no commercial price yet. Stem cell islet therapy for type 1 diabetes is available only in clinical research studies in China. Other type 1 options are priced after a specialist assessment.


Does insurance cover diabetes stem cell therapy in China?

The Boao treatment is self-paid. Patients with international health insurance should check their policy directly, as cover for treatment abroad varies.


Is the price fixed?

The per-infusion price is officially published. The total depends on the number of infusions recommended and on travel choices, so patients should ask for a written, itemized quote.


How long do patients need to stay in China?

Around three weeks for the Boao program, covering evaluation and three weekly infusions.


How ChinaCureLink Can Help


ChinaCureLink, as an affiliate of Medebound HEALTH — a New York–based medical concierge company founded by U.S. physicians, recognized by Forbes, with over 10 years of experience and more than 3,000 patients served traveling to the United States and China — brings institutional credibility to every case it handles.


ChinaCureLink represents the patient, not any specific hospital, and charges no fee to apply to hospitals, only a moderate fee for on-site support in China. The process starts with a free advisory call. ChinaCureLink then compares up to three suitable hospitals or specialists, arranges a video second opinion with the patient's chosen option, and, if the patient proceeds, coordinates records and translation, hospital communication, treatment planning, travel and in-China support.


What Patients Say About ChinaCureLink & Medebound HEALTH


China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.

 

Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot

Medebound HEALTH's online testimonials. Learn More


Final Thoughts


Stem cell therapy for diabetes in China represents one of the most closely watched areas in regenerative medicine today. While promising developments continue to emerge, patients should approach treatment decisions with realistic expectations and careful medical guidance.


With an official price per infusion, patients considering stem cell therapy for type 2 diabetes can now plan a realistic budget before travelling. Because eligibility and the number of infusions differ between patients, a records review is the best first step to confirm the total cost for a specific case.


Ready to confirm the total cost? → Request a Preliminary Case Review


You may also like:


References


About ChinaCurelink


ChinaCurelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.


We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.


ChinaCurelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient it serves.


bottom of page